Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REST: isatuximab + bortezomib + lenalidomide with minimal dexamethasone in transplant-ineligible NDMM
2023-510194-34-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Oslo University Hospital. Primary endpoint: Minimal residual disease (MRD) negativity rate within first 18 cycles. Planned start Oct 2024; status: authorised.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-510194-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510194-34-00.